Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role

Hao Zhang; Ruixuan Wang; Zeyu Wang; Wantao Wu; Nan Zhang; Longbo Zhang; Jason Hu; Peng Luo; Jian Zhang; Zaoqu Liu; Songshan Feng; Yun Peng; Zhengzheng Liu; Quan Cheng

Biomedicine & Pharmacotherapy (Dec 2022)

Molecular insight into pentraxin-3: Update advances in innate immunity, inflammation, tissue remodeling, diseases, and drug role

Hao Zhang,
Ruixuan Wang,
Zeyu Wang,
Wantao Wu,
Nan Zhang,
Longbo Zhang,
Jason Hu,
Peng Luo,
Jian Zhang,
Zaoqu Liu,
Songshan Feng,
Yun Peng,
Zhengzheng Liu,
Quan Cheng

Affiliations

Hao Zhang: Department of Neurosurgery, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China; Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University, China
Ruixuan Wang: Department of Oncology, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Zeyu Wang: Department of Neurosurgery, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Wantao Wu: Department of Oncology, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Nan Zhang: Department of Neurosurgery, Xiangya Hospital, Central South University, China; One-third Lab, College of Bioinformatics Science and Technology, Harbin Medical University, China
Longbo Zhang: Department of Neurosurgery, Xiangya Hospital, Central South University, China; Department of Neurosurgery, and Department of Cellular & Molecular Physiology,Yale University School of Medicine, USA; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Jason Hu: Department of Neonatology, Yale University School of Medicine, USA
Peng Luo: Department of Oncology, Zhujiang Hospital, Southern Medical University, China
Jian Zhang: Department of Oncology, Zhujiang Hospital, Southern Medical University, China
Zaoqu Liu: Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, China
Songshan Feng: Department of Neurosurgery, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Yun Peng: Department of Geriatrics, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China
Zhengzheng Liu: Department of Oncology, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China; Corresponding author at: Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Quan Cheng: Department of Neurosurgery, Xiangya Hospital, Central South University, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, China; Corresponding author at: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.

Journal volume & issue: Vol. 156
p. 113783

Abstract

Read online

Pentraxin-3 (PTX3) is the prototype of the long pentraxin subfamily, an acute-phase protein consisting of a C-terminal pentraxin domain and a unique N-terminal domain. PTX3 was initially isolated from human umbilical vein endothelial cells and human FS-4 fibroblasts. It was subsequently found to be also produced by synoviocytes, chondrocytes, osteoblasts, smooth muscle cells, myeloid dendritic cells, epithelial cells, and tumor cells. Various modulatory factors, such as miRNAs, cytokines, drugs, and hypoxic conditions, could regulate the expression level of PTX3. PTX3 is essential in regulating innate immunity, inflammation, angiogenesis, and tissue remodeling. Besides, PTX3 may play dual (pro-tumor and anti-tumor) roles in oncogenesis. PTX3 is involved in the occurrence and development of many non-cancerous diseases, including COVID-19, and might be a potential biomarker indicating the prognosis, activity,and severity of diseases. In this review, we summarize and discuss the potential roles of PTX3 in the oncogenesis and pathogenesis of non-cancerous diseases and potential targeted therapies based on PTX3.

Published in Biomedicine & Pharmacotherapy

ISSN: 0753-3322 (Print); 1950-6007 (Online)
Publisher: Elsevier
Country of publisher: France
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: https://www.journals.elsevier.com/biomedicine-and-pharmacotherapy

About the journal

Abstract

Keywords